ClinicalTrials.gg
Sign In
CompletedNCT03886142Updated Jan 18, 2020

Platelet Rich Plasma Versus Radio Frequency for Chronic Knee Arthritis

An interventional study of radiofrequency and platelet rich plasma injection in Osteo Arthritis Knee and Pain, Chronic, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2018, registered Mar 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Study summary

Osteoarthritis (OA) affects aged above 45 years. RF has been used for several painful conditions. There have been a few attempts to use RF current for the treatment of painful conditions of joints of the extremities. It was also used for the treatment of painful conditions of the hip joint.

02

Conditions studied

  • Osteo Arthritis Knee
  • Pain, Chronic

Browse trials for

03

In context

Chronic Pain

2,999 studies on the registry are indexed under Chronic Pain; 706 are open to participants now.

This study's enrollment of 200 is above the median of 60 across 2,209 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Assiut University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • osteoarthritis knee

Exclusion criteria

Exclusion Criteria:

  • coaguloapthy
  • patient refusal
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    radiofrequency

    genicular nerves pulsed radiofrequency

    Procedure: radiofrequency

  • Active comparator
    intra-articular platelet rich plasma

    injection of platelet rich plasma in the affected joint

    Procedure: platelet rich plasma injection

Interventions

  • Procedureradiofrequency

    radiofrequency of the genicular nerves

  • Procedureplatelet rich plasma injection

    intra articular injection of platelet rich plasma

06

What researchers measure

Primary outcomes

  1. pain visual analog scale

    assessment of visual analog scale (VAS) VAS of zero means no pain, and 10 means sever pain

    Time frame: 12 months

07

Study locations

1 site
  • Emad Zarief Kamel Said
    Asyut, 71111, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Oct 2019, 13 months.

Of 1,209 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's 13 months is below that.

Counting every sponsor, half of 1,296 studies reached it within 21 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2019
First posted
Mar 22, 2019
StartActual
Sep 27, 2018
Primary completionActual
Oct 30, 2019
CompletionActual
Nov 30, 2019
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03886142
Lead sponsor
Assiut University
Responsible party
Emad Zarief , MD (Clinical Professor, Assiut University) — Principal investigator
First posted
Mar 22, 2019
Start date
Sep 27, 2018
Primary completion
Oct 30, 2019
Completion
Nov 30, 2019
Last update
Jan 18, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Chronic Pain →

Other studies from this sponsor

Assiut University →

Start the discussion